Lege Artis Medicinae

[Type 2 diabetes: what is the role of a General Practitioner in the treatment of diabetes?]

TORZSA Péter, OLÁH Ilona, HARGITTAY Csenge, KALABAY László

DECEMBER 10, 2018

Lege Artis Medicinae - 2018;28(11-12)

[The 2017 National Guidelines of the Hun­garian Diabetes Association emphasize the individual treatment of diabetic patients and the strong, goal-oriented regulation of carbohydrate metabolism from recogni­tion on. Beside monotherapy, primary dual or triple combination therapy may be applied in the treatment of patients. In primary care it’s the treatment of patients with type 2 diabetes where there is a lot to be done. We hope that the everyday use of the Professional Guidelines will contribute to a more successful diabetic care by General Practitioners (GPs). The holistic care of the GP’s team plays an important role in the primary, secondary and tertiary prevention of Type 2 diabetes, which accounts for more than 90% of all diabetic cases. ]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Saluting Semmelweis on the 200th Anniversary of his Birth ]

GAZDA István

Lege Artis Medicinae

[The Nobel Prize in Medicine 2018 ]

KOVÁCS Ferenc

Lege Artis Medicinae

[The Great Acceleration]

BRYS Zoltán

Lege Artis Medicinae

[Mastitis and breastfeeding]

UNGVÁRY Renáta, MIKÓ-BARÁTH Eszter, KISS Eleonóra

[Various degrees of mastitis affect a significant percentage of breastfeeding mothers. Prevention and effective treatment are important public health issues due to the severe pain, malaise, high fever, and possible complications. Among other causes for early termination of breastfeeding, the most prominent reasons are the pain, prolonged healing, abscess due to mastitis and the frequent recurrence of the disease. Proper management of mastitis and alleviating the symptoms influence the length of breastfeeding and hence leads to a positive outcome for both the mother’s and her child’s long term health. Nevertheless, there are inconsistencies worldwide regarding the diagnosis, cure and prevention of mastitis. The treatments are done mostly on empirical basis. Even though numerous articles have been published on the subject, the unequivocal results are yet to come. This overview summarizes the current knowledge and the dilemmas about mastitis as well as the prevention opportunities and therapies. It also discusses the new results on breastmilk microbiome research, which might change the approach towards mastitis treatment.]

Lege Artis Medicinae

[Modalities of the therapy of patients with high cardiovascular risk]

FARSANG Csaba

[International and Hungarian guidelines emphasize the need of the combinations in the therapy of hypertension. Single pill combinations (SPC) are preferred. The importance of the treatment reducing cardiovascular risk is underlined by the fact that in most hypertensive patients other cardiovascular risk factors, among them most frequently dyslipidemia is present. In addition to antihypertensive drugs these patients should be treated also with those decreasing plasma lipids. Adherence / persistence to therapy of patients is greatly improved by the use of single pill combinations. Today we also have SPCs decreasing both, blood pressure and plasma lipids. Among them there is the combination containing amlodipine and atorvastatin. Several international and Hungarian clinical studies have been conducted. Results of these investigations have been described in several publications. In this paper I summarise the most important results of some of these studies. ]

All articles in the issue

Related contents

Clinical Neuroscience

Positive airway pressure normalizes glucose metabolism in obstructive sleep apnea independent of diabetes and obesity

KABELOĞLU Vasfiye, SENEL Benbir Gulçin, KARADENIZ Derya

The relationship among obstructive sleep apnea syndrome (OSAS), type 2 diabetes mellitus (DM2) and obesity is very complex and multi-directional. Obesity and increased visceral fat are important perpetuating factors for DM2 in patients with OSAS. On the other hand, OSAS itself leads to obesity by causing both leptin and insulin resistance as a consequence of activation of the sympathetic nervous system. Risk for developing DM2 further increases in patients with OSAS and obesity. Data regarding effects of positive airway pressure (PAP) therapy, gold standard treatment for OSAS, on glycemic control were inconsistent due to variability in duration of and adherence to PAP therapy. In our cohort study we investigated effects of PAP treatment on glucose metabolism in normal-weighted non-diabetic OSAS patients, in obese non-diabetic OSAS patients, and in OSAS patients with DM2. We prospectively analyzed 67 patients diagnosed with OSAS and documented to be effectively treated with PAP therapy for three months. Apnea-hypopnea index was highest in the diabetic group, being significantly higher than in the normal-weighted group (p=0.021). Mean HOMA values were significantly higher in obese (p=0.002) and diabetic group (p=0.001) than normal-weighted group; the differences were still significant after PAP therapy. HbA1c levels were significantly higher in diabetic group compared to those in normal-weighted (p=0.012) and obese (p=0.001) groups. After PAP treatment, decrease in HbA1c levels were significant in normal-weighted (p=0.008), obese (p=0.034), and diabetic (p=0.011) groups. There was no correlation with the change in HbA1c levels and age (p=0.212), BMI (p=0.322), AHI (p=0.098) or oxygen levels (p=0.122). Our study showed that treatment of OSAS by PAP therapy offers beneficial effect on glucose metabolism, not only in diabetic patients, but also in obese and normal-weighted OSAS patients. Although data regarding overall effects of PAP therapy on glycemic control present contradictory results in the literature, it should be emphasized that duration and adherence to PAP therapy were main determinants for beneficial outcome of treatment.

Lege Artis Medicinae

[A remarkably successful therapy with gliclazid treatment in type 2 diabetes mellitus]

KIS János Tibor

[INTRODUCTION - Sulfonylureas have become sidelined as second-line preparations as their use has been associated with an increased occurrence of weight gain and hypoglykaemia. In the case reported, however, therapeutic goals have been achieved with the use of gliclazid. CASE REPORT - A 45-year-old man with type 2 diabetes mellitus was using a metformin XR preparation. His HbA1c level was high and his main complaint was distention. His abdominal complaint was also obstructing his diet. Because of the high HbA1c level and overweight I initiated incretin-mimetic treatment. Due to the worsening of abdominal complaints I replaced the treatment with gliclazid, after thoroughly informing the patient. With gliclazid treatment the patient's abdominal complaints subdued, he was able to maintain his diet, lost 14 kg in three months and the parameters of his carbohydrate metabolism normalised. CONCLUSION - In case of abdominal complaints, a repeated anamnesis of the diet can reveal metformin intolerance. In such cases, the use of gliclazid can lead to therapeutic success with no gastrointestinal adverse effects.]

Lege Artis Medicinae

[THE PROBLEM OF CHILDHOOD OBESITY]

RODÉ Magdolna

[Obesity represents a major public health problem in both developed and developing countries having rapidly increased in prevalence in the past two decades. Childhood obesity is of particular concern. Two of its associated diseases require special attention; metabolic syndrome and type 2 diabetes one of its components that are increasingly diagnosed in childhood. A key to prevention and treatment is healthy lifestyle. The importance of education to healthy lifestyle from early childhood cannot be overemphasized.]

Lege Artis Medicinae

[Switching from human basis-bolus insulin treatment to analog insulins, from clinical aspects]

KIS János Tibor

[During treatment of patients with type 2 diabetes, early insulin treatment improves beta cell function, slows the progression of the disease and improves glycaemic values in the long term. In these cases, the strictest glycaemic target values can be achieved by basal-bolus insulin treatment. Furthermore, the development of chronic complications can be halted most effectively by normoglycaemia. It is a special task to switch from human basal-bolus insulin treatment to analog insulins. The author presents practical, clinical aspects of this switching through a case study.]

Image challenge

What do you see on the feet of the diabetic patient?